Table 3 Summary on the preparation and therapeutic activity of various BP-based preparations for postoperative treatment of tumors in solid tissues
From: Black phosphorous nanomaterials as a new paradigm for postoperative tumor treatment regimens
Carrier substrate | Therapeutic additive | Tumor indication | Antitumor mechanism | Wound healing mechanism | Refs. |
|---|---|---|---|---|---|
PDLLA-PEG‐PDLLA: PLEL hydrogel | No | Resected HeLa tumors | PTT | PTT-mediated antibacterial effect | [83] |
Gelatin hydrogels | No | Resected breast cancer | PTT | PTT-enhanced formation of lipid droplets and adipogenic related genes, hydrogel facilitated migration and infiltration of normal cells | [84] |
Agarose hydrogel | Stress granule inhibitor Emetine | Hepatocellular carcinoma | Emetine suppresses stress granule formation to sensitize tumors for PTT | Not mentioned | [85] |
Cellulose hydrogel | No | Melanoma, hepato-carcinoma and reticulum cell sarcoma | PTT | Not mentioned | [86] |
Agarose hydrogel | Doxorubicin | Breast cancer, cervical cancer, lung carcinoma, melanoma | PTT, PTT-triggered drug release | Not mentioned | [87] |
Gelatin-PCL nanofibrous scaffold | Doxorubicin | Resected melanoma | PTT, PTT-triggered drug release | Release of phosphates and phosphonates, photothermal stimulation of ERK1/2 and PI3K/Akt healing pathways | [88] |
BPs are first coated with tumor cell membrane then loaded into hyaluronic acid/pluronic F-127 hydrogels | PD-1 antibody, GM-CSF and lipopolysaccharide | Triple negative breast cancer | PTT-stimulated cross-presentation by APCs and PTT-triggered aPD-1 release | Not mentioned | [89] |
NIPAM hydrogel | γδ T cell agonist zoledronate | Breast cancer, bladder cancer | PTT, PTT-triggered zoledronate release | Not mentioned | [90] |
PPS-PAA-PEG vesicle | Ag+ions | Triple negative breast cancer | PDT, PDT/Ag+ stimulated antitumor immune responses | Ag+-mediated antibacterial effects | [96] |